MAB RESOURCES · August 23rd, 2021
STELFONTA: A New Way to Treat Mast Cell Tumors in Dogs
STELFONTA (tigilanol tiglate injection) is an innovative and effective treatment for mast cell tumors (MCTs) in dogs. It is indicated for the treatment of non-metastatic cutaneous mast cell tumors located all over the body and non-metastatic subcutaneous mast cell tumors located at, or distal to, the elbow or the hock. This single intratumoral injection lets you treat MCTs without surgery or anesthesia.
Some breeds, like Shar-Peis, Boxers, Golden Retrievers, Labrador Retrievers, French Bulldogs, and American Staffordshire Terriers are more likely to develop MCTs than other breeds. Older dogs (those averaging around eight years old) are also primarily affected.
How It Works
STELFONTA is injected directly into the tumor. It will cause tumor necrosis and promote healing of the tissue deficit by the second intention, with minimal scar formation. STELFONTA starts working within two hours, and tumors are typically destroyed by seven days.
Always administer a corticosteroid (e.g., prednisone or prednisolone), an H1 receptor blocking agent (e.g., diphenhydramine), and an H2 receptor blocking agent (e.g., famotidine) when using STELFONTA. This will decrease the potential for severe systemic adverse reactions from mast cell degranulation, including death.
Many oncologists and primary care veterinarians have tried STELFONTA and are very satisfied with the results. In clinical trials, STELFONTA removed 75% of mast cell tumors with one injection and 87% of the tumors with one or two injections.
You can find more information about STELFONTA for your clinic and your clients at: https://vet-us.virbac.com/stelfonta